DNA polymerase β contains a functional nuclear localization signal at its N-terminus

Thomas W. Kirby, Natalie R. Gassman, Cassandra E. Smith, Ming-Lang Zhao, Julie K. Horton, Samuel H. Wilson and Robert E. London*

National Institute of Environmental Health Sciences, Genome Integrity and Structural Biology Laboratory, National Institutes of Health, Research Triangle Park, NC 27709, USA

Received July 13, 2016; Revised November 15, 2016; Editorial Decision November 30, 2016; Accepted December 02, 2016

ABSTRACT

DNA polymerase β (pol β) requires nuclear localization to fulfill its DNA repair function. Although its small size has been interpreted to imply the absence of a need for active nuclear import, sequence and structural analysis suggests that a monopartite nuclear localization signal (NLS) may reside in the N-terminal lyase domain. Binding of this domain to Importin α1 (Impα1) was confirmed by gel filtration and NMR studies. Affinity was quantified by fluorescence polarization analysis of a fluorescein-tagged peptide corresponding to pol β residues 2–13. These studies indicate high affinity binding, characterized by a low micromolar Kd, that is selective for the murine Importin α1 (mImpα1) minor site, with the Kd strengthening to ~140 nM for the full lyase domain (residues 2–87). A further reduction in Kd is obtained in binding studies with human Importin α5 (hImpα5), which in some cases has been demonstrated to bind small domains connected to the NLS. The role of this NLS was confirmed by fluorescent imaging of wild-type and NLS-mutated pol β(R45S,K55S) in mouse embryonic fibroblasts lacking endogenous pol β. Together these data demonstrate that pol β contains a specific NLS sequence in the N-terminal lyase domain that promotes transport of the protein independent of its interaction partners. Active nuclear uptake allows development of a nuclear/cytosolic concentration gradient against a background of passive diffusion.

INTRODUCTION

Efficient DNA repair is dependent on the recruitment of damage-dependent polymerases to the cell nucleus. DNA polymerase β (pol β) plays a key role in base excision repair (1), as well as participating in other repair pathways (2–4) and in lesion bypass (5–12). The strong relationship between functional mutations in pol β and the development and progression of cancer is increasingly substantiated in many, although not all studies (13–21). Variations in the expression levels of pol β and other components of the base excision repair complexes have been reported to be associated with various pathologies, and particularly with cancer (22–28). In addition to dysregulated expression levels, altered subcellular distribution provides another increasingly appreciated mechanism for perturbing nuclear protein concentrations, resulting in cellular dysfunction and disease (29–32). Consistent with this mechanism, a variant form of Xeroderma Pigmentosum was recently determined to result from a mutation in the nuclear localization signal (NLS) of the translesion repair enzyme DNA polymerase η (33). Altered nuclear levels of the DNA repair proteins aprataxin and DNA ligase I that have been connected to Achalasia-Addisonianism-Alacrimia (Tripe A) syndrome and other functional impairments also have been demonstrated to result from mutated or altered expression levels of the nuclear pore protein ALADIN (34–36).

In order to fulfill their roles in DNA repair, family X DNA polymerases (pol X) require nuclear localization. Among the four mammalian pol X enzymes, three: pol μ; pol λ; and terminal deoxynucleotidyl transferase contain a putative NLS, while pol β is generally thought to lack an NLS motif (37–42). Consequently, pol β nuclear localization has been thought to depend on co-transport with other repair proteins to which it binds, or to depend on its small size allowing it to diffuse through the nuclear pore without reliance on active nuclear uptake (43,44). Pol β has been reported to interact with other DNA repair proteins that contain NLS sequences (45–51). However, detailed structural information and binding affinity data are available only for the interaction with XRCC1 (52–54). XRCC1 is reported to mediate the co-transport of DNA Ligase 3α (55,56) and

*To whom correspondence should be addressed. Tel: +1 919 541 4879; Fax: +1 919 541 5707; Email: london@niehs.nih.gov

Present addresses:
Natalie R. Gassman, University of South Alabama Mitchell Cancer Institute, Molecular & Metabolic Oncology, 1660 Springhill Ave, Mobile, AL 36604-1405, USA.
Cassandra Smith, University of Colorado School of Medicine, Anschutz Medical Campus, Campus Box: C296 AMC, Aurora, CO 80045, USA.

Published by Oxford University Press on behalf of Nucleic Acids Research 2016.
JWA (57) into the nucleus, and so it might also facilitate nuclear transport of other XRCC1-associated proteins, including pol β. Nevertheless, not all XRCC1 binding partners are efficiently co-transported into the nucleus, as is apparent from studies of aprataxin localization (34,36). Furthermore, there is increasing evidence that some of the repair functions of pol β do not require XRCC1 (58–60). Hence, it would make functional sense for the nuclear localization of pol β not to be completely dependent on XRCC1 binding and co-transport.

Despite the prevailing consensus that pol β lacks an NLS, the enzyme does contain a string of highly conserved, basic residues at its N-terminus, and nearly all available crystal structures indicate that ~10 N-terminal residues are disordered (Supplementary Figure S1). These characteristics led us to conclude that pol β might possess a classical, monopartite NLS at its extreme N-terminus. To evaluate this possibility, we have undertaken studies of the interaction of the N-terminal lyase domain of pol β (residues 2–87) with murine Importin α1 (mImpα1) as well as with human Importin α5 (hImpα5). Fluorescence anisotropy studies using a fluorescein derivative of the N-terminal pol β peptide (residues 2–13) in combination with wild-type or mutated forms of mouse Impα1/IBB provide a quantitative description of this interaction and demonstrate specificity for the minor binding pocket of mImpα1. These in vitro results are further supported by immunofluorescent staining of cells containing pol β with the wild-type or mutated NLS (R4S,K5S), where a strong reduction in nuclear localization is seen for cells expressing the mutated NLS sequence.

MATERIALS AND METHODS

MATERIALS AND METHODS

Materials

The fluorescein-labeled pol β NLS peptide: S3KRKAPQETLNGG14-Lys(FITC), used for fluorescence polarization assays, was obtained from Genscript at a purity level of > 90%. Methyl methanesulfonate (MMS) was from Sigma-Aldrich. Following a strategy used previously (61), we studied a pol β complex with a double-hairpin that forms a one-nucleotide gapped double-hairpin DNA substrate and 0.14 mM of the non-hydrolyzable nucleoside triphosphate 2′-[α,β-methylene]triphosphate (dAPCPP) was obtained from Jena Bioscience.

Protein expression

The [methyl-13C]methionine-labeled wild-type pol β and the NLS variant pol β (R4S,K5S) were prepared as described previously (62) by growth of the plasmid containing Escherichia coli on a medium containing [methyl-13C]methionine (CIL, Cambridge, MA). U-[15N] pol β lyase domain was expressed in E. coli BL21(DE3) grown in M9 minimal medium containing 13NH4Cl as the sole nitrogen source. U-[2H, 15N] pol β was expressed in E. coli BL21(DE3) grown in M9 deuterated (99% D2O) medium containing U-[2H] glycerol and 15NH4Cl as the sole carbon and nitrogen sources. The expressed proteins were prepared as described previously (17). The R4S,K5S mutations, chosen in order to preserve the hydrophilicity of the NLS residues while reducing the interaction with Impα, were generated using the QuikChange kit (Agilent Technologies). The protein concentrations were determined using 280 nm extinction coefficients of 20,088 M⁻¹ cm⁻¹ for full-length polymerases and 3591 M⁻¹ cm⁻¹ for the isolated lyase domains.

His-tagged mImpα1 with the Importin β binding domain (IBB) deleted (mImpα1ΔIBB) and its major pocket variant (mImpα1ΔIBB[W184R/W231R]) were prepared as described previously (56). The minor binding pocket double mutant (mImpα1ΔIBB[W357R/W399R]) was created using the QuikChange kit (Agilent). C-terminal His-tagged human Importin α5, corresponding to residues 66–512, (hImpα5ΔIBB) was purchased from Genscript and cloned into the pET30 expression vector. All clones were sequence verified. mImpα1ΔIBB[W357R/W399R] and hImpα5ΔIBB were expressed and purified by the IMAC and gel filtration protocol previously described (56). Protein concentrations were determined by the Edelhoch procedure (63).

NMR spectroscopy

For the mImpα1ΔIBB binding experiments, the samples contained 0.13 mM U-[15N]pol β and 0.13 mM mImpα1ΔIBB in a buffer consisting of 50 mM Tris-d1(D (pH 7.6), 150 mM KCl, 1 mM CDTA, 1 mM dithiothreitol (DTT), 0.1 mM AEBSF, 0.04% NaN3 and 50 μM DSS as an internal chemical shift standard, with 10% D2O for 1H,15N HSQC experiments and 100% D2O for 1H,13C HSQC experiments. For studies of the effects of the R4S,K5S mutation on pol β structure and function, the [methyl-13C]methionine-labeled pol β samples contained 0.1 mM pol β or the NLS-variant in the above 100% D2O buffer along with 0.11 mM of a 1-nucleotide gapped double-hairpin DNA substrate and 0.14 mM of the non-hydrolyzable nucleoside triphosphate substrate dAPCPP. Nuclear magnetic resonance (NMR) experiments were performed at 25°C on a Varian UNITY INOVA 600 or 800 MHz NMR spectrometer, using a 5 mm Varian 1H,13C,15N triple-resonance room-temperature or Cold Probe, equipped with actively shielded Z-gradients. The 1H,13C HSQC spectra were acquired using Varian’s gChsqc sequence. The spectra were processed using NMRPipe version 2.1 (64) and analyzed using NMRView version 5.0.4 (65). All spectra were processed using squared cosine bell apodization functions in all dimensions and forward-backward linear prediction in the indirect dimension (66).

Fluorescence polarization measurements

Apparent peptide dissociation constants were determined based on fluorescence polarization measurements using the fluorescein-labeled pol β NLS peptide as previously described (56). The binding constants for the interaction of pol β lyase domain with the Importin α constructs were determined by displacement by the FITC-labeled NLS peptide using a competition assay as previously described (56).
Chromatography
For an initial assessment of binding, a sample of mImpα1Δ1BB was mixed with a 2.8-fold excess of pol β lyase domain and the sample was eluted on a HiLoad 26/60 Superdex 200 column (GE Healthcare) with a buffer containing 20 mM Tris-HCl, pH 7.8, 125 mM NaCl, 2 mM DTT, 1 mM ethylenediaminetetraacetic acid. For the analytical gel filtration experiments, hImpα5Δ1BB was mixed with 2-fold excess of wild-type or the NLS variant pol β(R4S,K5S) lyase domain and the samples were eluted on a Superdex 200 10/300 GL column (GE Healthcare) with a buffer containing 20 mM HEPES, 125 mM NaCl, 5mM DTT, 1mM ethylenediaminetetraacetic acid, pH 7.4.

Cell lines and plasmids
Pol β null SV40-transformed mouse embryonic fibroblasts (MB38ΔA4) have been described previously (59). These cells were maintained in Dulbecco’s Modified Eagle’s medium (Life Technologies, Carlsbad, CA, USA) supplemented with GlutaMAX-1 (Life Technologies), 10% fetal bovine serum (Life Technologies, Carlsbad, CA, USA) in a 10% CO2 incubator at 34°C. NLS by replacing residues 4 and 5 with serines (R4S,K5S). The generation of stable cell lines.

Fluorescence Microscopy
Cells were seeded in 35 mm glass bottomed petri dishes (MatTek, Ashland, MA, USA) at 2 × 105 cells per dish and incubated in growth medium for 24 h. Initial cellular localization of wild-type pol β and the pol β(R4S,K5S) variant was conducted by transient transfection with the indicated pCDH531 construct using Lipofectamine™ 2000 24 h after cell plating. Twenty-four hours after transfection, cells were fixed with a 3.7% neutral buffered formaldehyde solution (Thermo Scientific) for 10 min at room temperature. Cells were then washed three times with phosphate-buffered saline (PBS, HyClone). After fixation, cells were permeabilized with 1% sodium dodecyl sulfate, as previously described (69). Cells were blocked in PBS + 1% bovine serum albumin for 30 min, and then incubated with anti-pol β antibody (1:200; ab26343, Abcam) for 1 h. Cells were washed three times with PBS, then incubated in Alexa 488 conjugated anti-rabbit secondary antibody (1:200; Life Technologies) and stained with DAPI NucBlue® Fixed Cell Stain ReadyProbes™ (Life Technologies) for 5 min. For stable wild-type pol β and pol β(R4S,K5S) expressing cell lines, cells were fixed 24 h after plating using the same procedure described for the transiently transfected cells. Immunofluorescent staining was also performed using a method similar to that given above except for use of an Alexa 546 conjugated anti-rabbit secondary antibody (1:2000; Life Technologies).

For transiently transfected cells, fluorescence images were acquired with a 40X C-Apochromat (numerical aperture 1.2) water immersion objective coupled to a Zeiss LSM510 META confocal microscope (Carl Zeiss MicroImaging). Multi-track configuration was used to ensure the absence of excitation cross-talk or emission bleed-through between channels. The 364 nm laser line was used at 3.5% maximum intensity, the 488 nm laser line was used at 10% of maximum intensity and the 543 nm laser line was used at 100% of maximum intensity. For pol β imaging, the 488 nm laser line with a 505–550 bandpass filter was used with a gain setting of 650 or less for all quantitative imaging acquisition. Gain setting was determined by examining pol β null cells stained with the pol β specific antibody (ab26343, Abcam) and the fluorescent secondary antibody. Non-specific staining was observed at gain settings higher than 700. Images of cells containing the non-specific stain at a gain setting of ∼850 showed a non-specific nuclear to cytoplasmic (βN/βC) ratio of 0.9 ± 0.01 (mean intensity ± standard error of mean). To control for this non-specific staining effect, a gain setting of 650 was chosen for imaging of the transiently transfected pol β null cells, where non-specific staining throughout the cell was no longer observed. RFP imaging was done using the 543 nm laser line with a 560–615 bandpass to confirm the presence of transfected pol β in the pol β null cells, since transfection efficiency in the cells was typically 50–60%. DAPI imaging was with the 364 nm laser line and 385–470 bandpass filter. Two-dimensional images were acquired and DAPI staining was used to select the best focal plane for nuclear imaging. Images were acquired with
RESULTS

The N-terminal lyase domain of pol β binds to Impα1ΔIBB

An initial in silico analysis of pol β using the program NLS Mapper (72) identified an extended N-terminal 28 amino-acid sequence beginning at residue 3: KRKAPQETLNG-GITDMLTEANFEKVS, as a possible, though low-scoring, bipartite NLS. A bipartite type of interaction of this peptide with Impα would require complete unfolding of the N-terminal helix A (Supplementary Figure S1). Since even an L22P point mutation is sufficient to result in unfolding of the entire lyase domain (17), this NLS identification was rejected. However, further evaluation of the extensive structural database for pol β indicates that electron density is generally absent or very limited for residues preceding positions 10 or 11, indicating that the 10 N-terminal residues are disordered and readily available for additional interactions. Furthermore, helix A contains a pair of consecutive glycine residues at positions 13 and 14 that serve no obvious structural or functional role. Glycine residues are generally not particularly favorable for α-helix formation, e.g. (73,74), but consecutive glycine residues have been identified in several proteins that utilize a conformational switch (75,76).

We thus considered it feasible that the entire N-terminal sequence from S2-G14 could participate in interactions with an importin carrier protein, assuming M1 will be removed by methionine aminopeptidase (77,78).

Analysis of samples containing a mixture of the pol β lyase domain (residues 2–87) and mImpα1ΔIBB by gel filtration indicated an interaction between the two proteins (Supplementary Figure S2), where the ΔIBB construct lacking the autoinhibitory Importin β binding domain was used in order to expose the NLS binding pockets, as is customary in most NLS studies (43,56,79). Note that the mouse and human wild-type pol β sequences are identical for the first 19 amino acids so their NLS interactions should also be identical. The binding result prompted us to compare the \(^{1}H\text{-}^{15}N\) HSQC spectrum of U-[\(^{15}N\)] pol β lyase domain in the absence or presence of mImpα1ΔIBB (Figure 1A). As is immediately apparent from the spectra, the binding affinity is sufficient to yield a lyase domain-mImpα1ΔIBB complex that displays broadened lyase domain amide resonances. Several less severely broadened resonances correspond to residues in mobile loop regions of the domain. The loss of intensity in the HSQC experiment is consistent with a reduction in the transverse relaxation times resulting from formation of a complex of the 8 kDa lyase domain with the 50 kDa mImpα1ΔIBB.

In order to further characterize the interaction, similar studies were performed using the full-length U-[\(^{1}H\text{-}^{15}N\)] pol β. In this case, addition of mImpα1ΔIBB produces a domain-selective effect, reducing the intensity of most of the lyase domain amide resonances, while having a minimal effect on resonances corresponding to the polymerase domain (Figure 1B). An expanded view of the spectrum reveals a broadening pattern similar to that obtained for the isolated lyase domain (Supplementary Figure S3). These results indicate a lyase domain-specific interaction with mImpα1ΔIBB, allowing the flexibly linked polymerase

Cytotoxicity studies

Hypersensitivity to MMS is the hallmark phenotype of pol β deficiency. Cytotoxicity was determined by growth inhibition assays as described previously (70). Stably transfected cells (pol β WT 96, pol β(R4S,K5S) 18, and pol β null) were seeded in six-well dishes at a density of 40,000 cells/well. The following day they were treated for 1 h with a range of concentrations of MMS. Cells were then washed in Hanks’ balanced salt solution (Life Technologies) and fresh medium was added. Dishes were incubated for 6 to 7 days at 37°C in a 10% CO₂ incubator until untreated control cells were approximately 80% confluent. Cells (triplicate wells for each MMS concentration) were counted by a cell lysis procedure (71). Results were expressed as the number of cells in MMS-treated wells relative to untreated cells (% control growth).

Fluorescence intensity analysis

Images of the transiently and stably transfected cells were analyzed using MetaMorph (Molecular Devices, Sunnyvale, CA, USA). Nuclear and cytoplasmic boundaries were determined using the images taken from the DAPI and Alexa 488 or 546 channels, respectively. The intensity of the pol β for each of these regions was determined from the Alexa channel. The intensity indicates the relative amount of pol β that is localized to either cellular compartment. The ratio of the nuclear intensity of Alexa 488 or 546 to the cytoplasmic intensity of Alexa 488 or 546 was taken to represent the extent of nuclear localization. A total of 40–60 cells were analyzed in this manner for the transiently transfected cells, though non-specific staining could not be completely eliminated without significant loss of brightness in the stable cells. An optimal nuclear slice was determined, and images were acquired with a pin hole of 1 AU and a zoom of 1.0. Zen 2012 software was used for all image acquisition.

A pinhole of 1 airy unit, a zoom of 1.0. Zen 2009 software was used for all image acquisition.

For the stably transfected cell lines, fluorescence images were acquired with a 40X C-Apochromat (numerical aperture 1.2) water immersion objective coupled to a Zeiss LSM 780 confocal microscope. Multi-track configuration was used to ensure the absence of excitation cross-talk or emission bleed-through between channels. The 405 nm laser line with a 417–480 bandpass filter was used at 1% maximum intensity for DAPI imaging, and the 561 nm laser line with a 562–515 bandpass filter was used at 1.5% of maximum intensity for pol β imaging. A gain setting of 500 was used for all quantitative imaging acquisition. The gain setting was determined using the same non-specific staining method described for the transiently transfected cells, though non-specific staining could not be completely eliminated without significant loss of brightness in the stable cells. An optimal nuclear slice was determined, and images were acquired with a pin hole of 1 AU and a zoom of 1.0. Zen 2012 software was used for all image acquisition.

Nucleic Acids Research, 2017, Vol. 45, No. 4 1961
Figure 1. Nuclear magnetic resonance (NMR) characterization of the pol β-Importin α interaction. (A) Overlay of $^1$H-$^15$N HSQC spectra of 130 μM U-[15N] pol β(1-87) in the absence (blue) or the presence (red) of an equal concentration of mImportin1ΔIBB. (B) Overlay of $^1$H-$^15$N HSQC spectra of 130 μM U-$[^2]$H,$^15$N] pol β in the absence (blue) or the presence (red) of 130 μM mImportin1ΔIBB (an expanded view illustrating the selectivity of mImportin1-induced immobilization is shown in Supplementary Figure S3). (C) Schematic illustration of the domain-selective immobilization of pol β resulting from Importin α binding. The NMR buffer contained 50 mM Tris- d$_{11}$ (pH 7.6), 150 mM KCl, 1 mM CDTA, 1 mM dithiothreitol (DTT), 0.1 mM AEBSF, 0.04% NaN$_3$ and 50 μM DSS as an internal chemical shift standard, with 10% D$_2$O for the lock.
Affinity and specificity of the pol β NLS – Impα interaction

Additional insight into the pol β NLS-Impα interaction was derived from fluorescence polarization measurements utilizing a fluorescein-NLS peptide adduct. Fluorescence polarization studies were performed using full-length mImpα, the ΔIBB form lacking the Importin β binding domain, as well as two ΔIBB constructs in which either the major or minor binding pocket was blocked: major-site blocked analog, mImpαΔIBB(W184R,W241R); minor-site blocked analog, mImpαΔIBB(W357R,W399R). For both variant constructs, a pair of Trp residues that contribute to NLS binding is replaced by a pair of Arg residues that are expected to interact unfavorably with the positively charged NLS peptides (56). Titration curves showing the normalized fluorescence polarization as a function of the concentration of the mImpα analogs are shown in Figure 2, and apparent $K_d$ values are summarized in Table 1. Binding to full length Impα is weak, yielding a measured $K_d$ value of 54.3 μM, while in the absence of the N-terminal IBB domain, the apparent $K_d$ drops to 2.0 μM; this 27-fold increase in affinity demonstrates the specificity of the pol β peptide for the cargo-binding region of Impα. The titration studies using the major and minor site-blocked mImpαΔIBB analogs further demonstrate that the interaction is highly selective for the minor binding pocket of mImpα, with $K_d^{maj} = 225 \mu M$ and $K_d^{min} = 4.5 \mu M$ (Figure 2 and Table 1).

The NMR data shown in Figure 1 indicate that the entire lyase domain experiences substantial immobilization upon complex formation with mImpαΔIBB, suggesting the possibility that the interaction may also involve other lyase domain residues in addition to those of the N-terminal segment. This possibility is also suggested by crystallo-

NLS modification abolishes complex formation between hImpα and pol β lyase domain

In order to further characterize the interaction between Impα and the pol β lyase domain, we again made use of the R4S,K5S NLS variant of the domain. Analytical gel filtration experiments performed on mixtures of hImpαΔIBB and either wild-type or R4S,K5S lyase domain (Supplementary Figure S4) indicate that no stable complex of R4S,K5S lyase domain elutes from the column, while wild-type lyase domain does elute as a complex.
The conformational activation of pol β is not altered by NLS modification

As outlined previously, pol β undergoes a ligand dependent conformational activation when an incoming dNTP that is complementary to the templating base binds to the enzyme (61,62). This activation is conveniently monitored by NMR analysis of the methionine methyl resonances of [13CH3-Met] pol β. It was anticipated that mutational variation of the disordered N-terminal segment would not significantly influence the conformational response of the enzyme. This assumption was evaluated by comparing the substrate response of [methyl-13C]methionine-labeled pol β(R4S,K5S) with the response of the wild-type enzyme. Methionine resonances have been shown to be sensitive to proper folding, substrate binding, and catalytic activation when the correct incoming nucleotide is present (61,62). The results of these studies indicate no differences between wild-type pol β and pol β(R4S,K5S) in either the uncomplexed state or in the ternary complex with one-nucleotide gapped DNA and the non-hydrolyzable nucleotide analog dAPCPP (Figure 4). Hence, as expected, the introduction of these NLS mutations has no impact on the folding or substrate-dependent conformational responses of the enzyme, and the in vivo effects of the mutations may be attributable to localization differences.

Nuclear localization of wild-type and NLS-mutated pol β

In order to evaluate the nuclear localization role of the pol β Impα-binding motif, we evaluated the cellular distribution of both wild-type and NLS variant pol β transiently expressed in pol β null mouse embryonic fibroblasts. We studied wild-type pol β and an N-terminal analog: pol β(R4S,K5S) where residues 4 and 5 are replaced by serines. Fluorescent images were obtained for cells transiently expressing wild-type or pol β(R4S,K5S) (Figure 5). Consistent with expectations based on Impα binding affinity, the pol β(R4S,K5S) variant exhibited no significant localization preference for the nucleus (Figure 5). The nuclear/cytoplasmic ratio for wild-type pol β (βN/βC) was 2.22 ± 0.15, while the localization of the R4S,K5S variant was significantly lower, with a βN/βC ratio of 0.58 ± 0.02 (P < 0.001, Figure 5B). These results indicate that the binding data summarized in Table 1 correspond to a functional NLS for pol β. Further, the results indicate that all other contributions to the nuclear localization of pol β fail to significantly increase the βN/βC ratio.

---

**Table 1. pol β NLS dissociation constants**

| Ligand | Target | K_d (µM) |
|--------|--------|----------|
| SKRKAPQETLNGG[Lys(FITC)]<sup>a</sup> | mImpα1Δ1BB | 3.6 ± 0.4 |
| SKRKAPQETLNGG[Lys(FITC)]<sup>a</sup> | mImpα1 | 61.8 ± 1.7 |
| SKRKAPQETLNGG[Lys(FITC)]<sup>a</sup> | mImpα1Δ1BB (W357R,W399R) Minor site blocked | 225 ± 11 |
| SKRKAPQETLNGG[Lys(FITC)]<sup>a</sup> | mImpα1Δ1BB (W184R,W231R) Major site blocked | 4.5 ± 0.5 |
| SKRKAPQETLNGG[Lys(FITC)]<sup>a</sup> | Impα5Δ1BB | 0.720 ± 0.030 |
| Pol β lyase domain<sup>b</sup> | mImpα1Δ1BB | 0.140 ± 0.017 |
| Pol β(R4S,K5S) lyase domain<sup>b</sup> | Impα5Δ1BB | 530 ± 2 |
| Pol β lyase domain<sup>b</sup> | Impα5Δ1BB | 0.017 ± 0.006 |

<sup>a</sup>K_d values determined by fluorescence polarization.

<sup>b</sup>K_d determined by ligand displacement.
Figure 4. Substrate-dependent conformational activation of pol β is unchanged by mutations in the NLS sequence. The $^1$H-$^1$C HSQC spectra of [13CH3-Met] pol β and a ternary complex of gapped DNA•Mg-dAPCPP•pol β (black) are overlaid with spectra of [13CH3-Met] pol β(R4S,K5S) and a complex of gapped DNA•Mg-dAPCPP•pol β(R4S,K5S) (magenta). The arrows show the repositioning of the resonances in response to the addition of substrates. The N-terminal mutations apparently exert no effect on the conformational response of the enzyme to substrates.

Figure 5. Subcellular distribution of pol β. (A) The pol β (Alexa 488) panel shows the cellular distribution of wild-type pol β and the pol β(R4S,K5S) NLS variant transiently transfected into pol β null cells. The DAPI column (DNA staining) defines the cell nucleus. The Merge column superimposes the Alexa 488 stain and the nuclear stain to reveal the extent of nuclear localization for each pol β construct. Representative cells are shown. Scale bar is 10 μm. (B) Bar graph showing the effect on nuclear localization of mutations made to the pol β NLS. The data represent imaging of between 40 and 60 cells and error bars show the standard error of the mean.

To confirm that localization was due to the NLS mutation and was not a result of the transient expression of pol β(R4S,K5S), we created stable cell lines expressing either wild-type pol β (pol β WT clone 96) or the pol β(R4S,K5S) variant (pol β(R4S,K5S) clone 18) in the pol β null background, and examined the nuclear localization by fluorescence microscopy (Figure 6). Inspection of the images reveals a localization pattern that is qualitatively similar to that observed for the transiently transfected cells. The images shown in columns 1 and 3 of Figure 6A demonstrate a decrease in the $\beta_N/\beta_C$ ratio for cells expressing the pol β(R4S,K5S) variant—$\beta_N/\beta_C$ ratio = 1.26 ± 0.07—relative
Figure 6. Distribution of wild-type pol β and pol β(R4S,K5S) NLS variant in stable cell lines. (A) Fluorescence images of cells stained with a pol β primary and fluorescent secondary antibody, with DAPI to indicate nuclear location and merged displays as described in Figure 5. Representative cells are shown. (B) Bar graph showing the effect on nuclear localization of mutations made to the pol β NLS. The data represent imaging of 56 and 49 cells, for pol β WT 96 and pol β(R4S,K5S) 18, respectively. Error bars show the standard error of the mean.

to cells expressing pol β wild-type enzyme—$\beta_N/\beta_C$ ratio = 3.06 ± 0.32 (Figure 6B).

We also evaluated the possible contribution of XRCC1-mediated co-transport of pol β using fluorescence imaging of Xrcc1−/− cells. As shown in Supplementary Figure S5, the $\beta_N/\beta_C$ ratio was within the experimental error of the value for the cells containing XRCC1. Thus, despite the ability to form a high affinity XRCC1-pol β complex (52,54), XRCC1-mediated uptake does not significantly alter the nuclear/cytoplasmic ratio of pol β.

**Dependence of MMS sensitivity on a functional NLS**

Pol β has been demonstrated to play an important role in the protection of cells against MMS-induced cytotoxic DNA damage (1,58). In order to assess the possible importance of the putative pol β NLS for the repair activity of pol β, we challenged the stable cell lines expressing the wild-type or polβ(R4S,K5S) variant for 1 h with the alkylating agent MMS and then cultured them to assess viability. No significant difference in MMS sensitivity was observed between the two cell lines (Figure 7). Given that the mutant NLS does not alter the conformational activity of pol β (Figure 4), we conclude that in this assay, the decreased nuclear level of the pol β(R4S,K5S) variant remains above the threshold required for pol β-dependent base excision repair of MMS-induced damage. Repair of the alkylation damage is thus not limited by the availability of pol β at the lower concentration achieved in cells containing the NLS-mutated enzyme. The observed growth inhibition of the cells treated with higher MMS concentrations indicates a failure of all available repair pathways to deal with the damage.

**DISCUSSION**

The studies presented here demonstrate that: (i) pol β contains an unstructured N-terminal motif that is available for binding to Impα; (ii) the pol β-Impα interaction involves formation of a specific complex with the Impα minor site; (iii) stronger interactions are observed with hImpα5 than with mImpα1 and for the full lyase domain compared with
the N-terminal NLS peptide; (iv) mutating the putative pol β NLS to a non-binding sequence eliminates the interaction with Impα and significantly reduces the nuclear accumulation of the enzyme; (v) although reduced nuclear pol β levels may significantly impair the DNA repair functions of pol β, no effect was observed in the MMS cytotoxicity assay.

Although not initially anticipated, the specific preference of the pol β NLS for the Impα minor binding pocket is consistent with results in the literature. Ligands that effectivly target the Impα major site generally exhibit two characteristics: (i) a consensus binding motif defined as: K(K/R)X(K/R) (83), and (ii) a minimum of three residues N-terminal to the binding motif that make non-specific contacts with the Impα, often involving H-bond interactions with the backbone carbonyl groups (56). The pol β NLS lacks both of these characteristics; after removal of the N-terminal methionine by methionine aminopeptidase (77,78,89), only a single residue precedes the KRK motif. The pol β SKRKA sequence is, however, quite similar to other sequences shown to have high affinity for the Impα minor pocket (82,84), including the recently determined GKRKL minor site motif of the XRCC1 bipartite NLS (56). Comparative sequence analysis indicates that the KRKxP motif in pol β is highly conserved among higher euukaryotes (Supplementary Figure S6). In addition to the minor site binding motif, Pro7 ensures that the N-terminus does not form an extension of helix A1.

Mutations in the unstructured N-terminus of pol β have not been reported in studies of tumor-associated variants (15,19,90). Examination of the dbSNP indicates rare polymorphisms at positions 1, 8, and 11, but none have been reported for the critical KKRNR residues or for the immediately flanking residues that may bind directly to the minor site of Impα. Thus, the identified polymorphisms might at most be expected to exert a very weak effect on the Impα interaction. Conversely, the fact that an unstructured N-terminal sequence is so well conserved supports the conclusion that pol β NLS makes a significant contribution to the cellular functions of the enzyme.

Based on our results, the cellular distribution of pol β is, in principle, dependent on at least three transport pathways: (i) passive diffusion through the nuclear pore; (ii) possible co-transport involving XRCC1 or other DNA repair proteins; (iii) active nuclear uptake by NLS-dependent classical nuclear transport (Figure 8). Since pol β is well below the size threshold for passive diffusion (44), equilibration of the nuclear and cytoplasmic pools due to diffusion is likely to be important for this enzyme. For both transiently transfected and stable cell lines containing NLS-mutated pol β(R4S,K5S), our results were close to the ratio of 1.0 expected if passive transport plays a dominant role. The similar nuclear/cytoplasmic pol β ratios exhibited by the Xrccl+/+ and Xrccl−/− cells (Supplementary Figure S5), indicate that any additional nuclear uptake resulting from XRCC1-dependent co-transport is either absent or insufficient to significantly alter this ratio. Thus, pol β appears to be sufficiently small to preclude development of a significant nuclear concentration gradient in the absence of active transport. Alternatively, a nuclear/cytoplasmic pol β concentration gradient is developed in the presence of an NLS-dependent active transport process.

Given the apparent importance of pol β expression levels for optimizing genome stability (25,26,28), it is not surprising that this distribution is under the control of a functional NLS, rather than depending primarily on passive diffusion or co-transport mechanisms. Nuclear transport by the Impα/β system is bidirectional (91), so that nuclear import is determined by a combination of import and export rate constants:

\[
\frac{d\beta_{\text{N}}}{dt} = k_{\text{in}}\beta_{\text{C}} - k_{\text{out}}\beta_{\text{N}}, \quad \frac{d\beta_{\text{C}}}{dt} = k_{\text{out}}\beta_{\text{N}} - k_{\text{in}}\beta_{\text{C}}
\]

leading to a steady state ratio of the nuclear and cytosolic pol β pools given by:

\[
\frac{\beta_{\text{N}}}{\beta_{\text{C}}} = \frac{k_{\text{in}}}{k_{\text{out}}}
\]

If the only mechanism for nuclear transport were passive diffusion, which presumably contributes equally to \(k_{\text{in}}\) and \(k_{\text{out}}\), then the net nuclear excess of pol β would depend primarily on contributions from various binding interactions, such as the interaction with XRCC1, as well as on degradation processes, such as CHIP-mediated proteasomal degradation (60,92). Based on the schematic pathways shown in Figure 8, the lack of an effect of XRCC1 on pol β distribution (Supplementary Figure S5) is not surprising. If XRCC1 does function as a pol β co-transport protein, the nuclear XRCC1-pol β complex remains subject to dissociation, after which the small pol β molecule can exit the nucleus via passive diffusion. As in the example of pol β, histones are small enough to enter/exit the nucleus via passive diffusion, but also utilize NLS-dependent nuclear import, although involving different importins (93) as well as co-transport mechanisms (94). Thus, NLS-dependent uptake mechanisms provide a consistent basis for maintaining...
a net nuclear excess against a background of passive diffusion.

The position of the NLS at the N-terminus and the enhanced affinity found for the lysase domain further substantiate the important role that this domain plays in DNA repair (59). These results are also consistent with data indicating that at least a portion of the pol β repair function is independent of XRCC1 (58,59). Identification of a pol β NLS provides a new tool that can be used for altering the nuclear/cytosolic distribution of this critical repair enzyme, and for understanding the role that dysregulation of pol β subcellular distribution may play in the etiology of various diseases.

SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.

ACKNOWLEDGEMENTS
The authors are grateful to C. Jeff Tucker and to Dr Agnes K. Janoshazi at the NIEMS Fluorescence Microscopy and Imaging Center for their expert assistance with the implementation and analysis of the localization studies, and to Scott A. Gabel and Eugene F. DeRose for assistance with the experimental studies.

FUNDING
Intramural Research Program of the NIH, National Institute of Environmental Health Sciences [project number ZIA ES050111 to R.E.L. and project numbers Z01 ES050158 and ES050159 to S.H.W., R00ES023813 to N.R.G., in part]. Funding for open access charge: Intramural Research Program of the NIH, National Institute of Environmental Health Sciences [project number ZIA ES050111]. Conflict of interest statement. None declared.

REFERENCES
1. Sobol, R.W., Horton, J.K., Kuhn, R., Gu, H., Singhal, R.K., Prasad, R., Rajewsky, K. and Wilson, S.H. (1996) Requirement of mammalian DNA polymerase-β in base-excision repair. Nature, 379, 183–186.
2. Crespan, E., Czaban, T., Maga, G. and Hubscher, U. (2012) Microhomology-mediated DNA strand annealing and elongation by human DNA polymerases λ and β on normal and repetitive DNA sequences. Nucleic Acids Res., 40, 5577–5590.
3. London, R.E. (2015) The structural basis of XRCC1-mediated DNA repair. DNA Repair (Amst.), 30, 90–103.
4. Smith, C.A. and Okumoto, D.S. (1984) Nature of DNA repair synthesis resistant to inhibitors of polymerase α in human cells. Biochemistry, 23, 1383–1391.
5. Belousova, E.A., Maga, G., Fan, Y., Kubareva, E.A., Romanova, E.A., Lebedeva, N.A., Oretskaya, T.S. and Lavrik, O.I. (2010) DNA Polymerases β and β Bypass Thymine Glycol in Gapped DNA Structures. Biochemistry, 49, 4695–4704.
6. Hoffmann, J.S., Pillare, M.J., Maga, G., Podust, V., Hubscher, U. and Villani, G. (1995) DNA polymerase β bypasses in vitro a single d(GpG)-cisplatin adduct placed on codon 13 of the HRAS gene. Proc. Natl. Acad. Sci. U.S.A., 92, 5356–5360.
7. Jaiswal, A.S., Anjea, R., Sarkar, F.H., Ostrov, D.A. and Narayan, S. (2011) DNA polymerase β as a novel target for chemotherapeutic intervention of colorectal cancer. PLoS One, 6, e16691.
8. Nicolay, N.H., Helledge, T. and Sharma, R.A. (2012) Biological relevance of DNA polymerase β and translesion synthesis polymerases to cancer and its treatment. Curr. Mol. Pharmacol., 5, 54–67.
9. Smith, L.A., Makarova, A.V., Samson, L., Thiesen, K.E., Dhar, A. and Besho, T. (2012) Bypass of a psoralen DNA interstrand cross-link by DNA polymerases β, γ and δ in vitro. Biochemistry, 51, 8931–8938.
10. Stachek, G.C., Dalal, S., Donigan, K.A., Campisi, H., Hubscher, U., Glazer, P.M. (2010) Potentiation of temozolomide cytotoxicity by inhibition of DNA polymerase β is accentuated by BRCA2 mutation. Cancer Res., 70, 409–417.
11. Tang, J.B., Sviat, D., Trivedi, R.N., Wang, X.H., Goellner, E.M., Moore, B., Hamilton, R.L., Banerjee, B.A., Brown, A.R. and Sobol, R.W. (2011) N-methylpurine DNA glycosylase and DNA polymerase β modulate BER inhibitor potentiation of glioma cells to temozolomide. Neuro Oncol., 13, 471–486.
12. Trivedi, R.N., Wang, X.H., Jezelewicz, E., Goellner, E.M., Tang, J.B. and Sobol, R.W. (2008) Human methyl purine DNA glycosylase and DNA polymerase β expression collectively predict sensitivity to temozolomide. Mol. Pharmacol., 74, 505–516.
13. An, C.L., Chen, D. and Makridakis, N.M. (2001) Systematic biochemical analysis of somatic missense mutations in DNA polymerase β found in prostate cancer reveal alteration of enzymatic function. Hum. Mutat., 32, 415–423.
14. Dobashi, Y., Shuin, T., Tsuruga, H., Uemura, H., Torigoe, S. and Kubota, Y. (1994) DNA polymerase β gene mutation in human prostate cancer. Cancer Res., 54, 2827–2829.
15. Donigian, K.A., Sun, K.W., Nemec, A.A., Murphy, D.L., Cong, X., Northrup, V., Zelterman, D. and Sweasy, J.B. (2012) Human POLB gene is mutated in high percentage of colorectal tumors. J. Biol. Chem., 287, 23830–23839.
16. Iwanaga, A., Ouchiha, M., Miyazaki, K., Hirok, K. and Mukai, T. (1999) Functional mutation of DNA polymerase β found in human gastric cancer - inability of the base excision repair in vitro. Mutat. Res., 435, 121–128.
17. Kirby, T.W., DeRose, E.F., Beard, W.A., Shock, D.D., Wilson, S.H. and London, R.E. (2014) Substrate rescue of DNA polymerase β containing a catastrophic L22P mutation. Biochemistry, 53, 2413–2422.
18. Sliwinski, T., Ziembka, P., Morawiec, Z., Kowalski, M., Zadrozy, M. and Blasiak, J. (2007) Polymorphisms of the DNA polymerase γ gene in breast cancer. Breast Cancer Res. Treat., 103, 161–166.
19. Starcevic, D., Dalal, S. and Sweasy, J.B. (2004) Is there a link between DNA polymerase β and cancer? Cell Cycle, 3, 996–999.
20. Wallace, S.S., Murphy, D.L. and Sweasy, J.B. (2012) Base excision repair and cancer. Cancer Lett., 327, 73–89.
21. Simonelli, V., Delricco, M., Pali, D., Prasad, R., Wilson, S.H. and Dogliotti, L. (2009) Characterization of DNA polymerase β splicing variants in gastric cancer: the most frequent exon 2-deleted isoform is non-coding. J. Mol. Med., 77, 79–87.
22. Cabello, D.C., Ikeno, Y., Nysta, A., Basuttil, A., Anyangwe, N., Vigg, J., Matherly, L.H., Tucker, J.D. and Wilson, S.H., Richardson, A. et al. (2006) Haploinsufficiency in DNA polymerase β increases cancer risk with age and alters mortality rate. Cancer Res., 66, 7460–7465.
23. Srivastava, D.K., Husain, I., Arteaga, C.L. and Wilson, S.H. (1999) DNA polymerase β expression differences in selected human tumors and cell lines. Carcinogenesis, 20, 1049–1054.
24. Canitrot, Y., Cauiaux, C., Frechet, M., Bouayadi, K., Lesca, C., Salles, B. and Hoffmann, J.S. (1998) Overexpression of DNA polymerase β in cell results in a mutant phenotype and a decreased sensitivity to anticancer drugs. Proc. Natl. Acad. Sci. U.S.A., 95, 12586–12590.
25. Abdul-Fatah, T.M.A., Russell, R., Agarwalla, D., Moseley, P., Abayomi, M.A., Perry, C., Albarakati, N., Ball, G., Chan, S., Caldas, C. et al. (2014) DNA polymerase β deficiency is linked to aggressive breast cancer: A comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts. Mol. Oncol., 8, 520–532.
26. Bergoglio, V., Pillaire, M.J., Lacroix-Triki, M., Bayeaud-Messina, B., Canitrot, Y., Birth, A., Gares, M., Wright, M., Deslo, G., Loeb, L.A. et al. (2002) Deregulated DNA polymerase β induces chromosome instability and tumorigenesis. Cancer Res., 62, 3511–3514.
27. Scanlon, K.J., Kashanisabet, M. and Miyachi, H. (1989) Differential gene expression in human cancer-cells resistant to cisplatin. Cancer Invest., 7, 581–587.
28. Sobol,R.W., Foley,J.F., Nyska,A., Davidson,M.G. and Wilson,S.H. (2003) Regulated over-expression of DNA polymerase β mediates early onset cataract in mice. *DNA Repair (Amst)*, 2, 609–622.

29. McLane,L.M. and Corbett,A.H. (2009) Nuclear localization signals and human disease. *IUBMB Life*, 61, 697–706.

30. Hung,M.C. and Link,W. (2011) Protein localization in disease and therapy. *J. Cell Sci.*, 124, 3381–3392.

31. Knudsen,N.O., Andersen,S.D., Lutzen,A., Nielsen,F.C. and Rasmussen,L.I. (2009) Nuclear translocation contributes to regulation of DNA excision repair activities. *DNA Repair (Amst)*, 8, 682–689.

32. Poletto,M., Lirussi,L., Wilson,D.M. and Tell,G. (2014) Nuclear localization signals modulate activity, assembly and nuclear accumulation of base excision repair proteins. *Mol. Biol. Cell*, 25, 1641–1652.

33. Opletalova,K., Bourillon,A., Yang,W., Pouvelle,C., Armier,J., Hirano,M., Furiya,Y., Asai,H., Yasui,A. and Ueno,S. (2006) The DNA-polymerase-X family: controllers of DNA quality? *EMBO J.*, 25, 1038–1043.

34. Tomkinson,A.E. and Tomkinson,A.E. (2015) Quantitative characterization of protein-protein complexes involved in base excision DNA repair. *Nucleic Acids Res.*, 43, 6009–6022.

35. Dimitriadis,E.K., Prasad,R., Vaske,M.K., Chen,L., Tomkinson,A.E., Lewis,M.S. and Wilson,S.H. (1998) Thermodynamics of human DNA ligase I trimerization and association with DNA polymerase β. *J. Biol. Chem.*, 273, 20540–20550.

36. Rasmussen,L.J. (2009) Nuclear translocation contributes to early onset cataract in mice. *Curr. Eye Res.*, 38, 3164–3170.

37. Shimazaki,N., Yoshida,K., Kobayashi,T., Toji,S., Tamai,K. and Tomkinson,A.E. (2000) Interaction of human apurinic endonuclease and DNA polymerase β with importin α. *J. Biol. Chem.*, 275, 19126–19133.

38. Saha,S., Raghupathy,S. and Datta,A. (2009) Functional role of a bipartite NLS. *Cell cycle*, 8, 4076–4086.

39. Savannah,A.M. and Finlay,C.B. (2015) Recent advances in the study of nuclear import. *Adv. Exp. Med. Biol.*, 824, 1–22.

40. Ramadan,K., Shevelev,I. and Hubscher,U. (2004) The lyase activity of the DNA repair scaffold XRCC1: uncovering the functional role of a bipartite NLS. *Nucleic Acids Res.*, 32, 494–499.

41. Schuelke,M. and Grassmann,N. (2006) Functional analysis of nuclear import and nuclear transport. *Biochem. Soc. Trans.*, 34, 1176–1181.

42. Martin,M.J. and London,R.E. (2010) Oxidative stress in the XRC1 complex. *Annu. Rev. Biochem.*, 79, 81–107.

43. Esteban,V., Gorospe,A., Costas,C., Martin,M.J. and London,R.E. (2005) Targeted disruption of the redox transition of the XRC1 complex. *Nucleic Acids Res.*, 33, 6095–6107.

44. Gavel,S.A., Smith,C.E., Cuneo,M.J., Mueller,G.A., Kirby,T.W., DeRose,E.F., Krahn,J.M. and London,R.E. (2014) Characterization of the nuclear localization of the DNA repair scaffold XRC1: uncovering the functional role of a bipartite NLS. *Sci. Rep.*, 5, 13405.

45. Psathakis,D., Mihalik,A., Tytell,S.J., Fedorov,A. and London,R.E. (2014) Characterization of the structural interaction of the single-strand-break repair protein, X-ray cross-complementing group 1, with DNA polymerase β. *Nucleic Acids Res.*, 41, 5808–5817.

46. Cuneo,M.J. and London,R.E. (2010) Restoration of nuclear-import failure caused by triple A syndrome and hypersensitivity to oxidative stress in triple A syndrome. *Proc. Natl. Acad. Sci. U.S.A.*, 107, 6805–6810.

47. Zhu,G. and Bax,A. (1992) Improved linear prediction of damped NMR signals using modified forward backward linear prediction. *Biochem. Biophys. Res. Commun.*, 183, 3164–3170.

48. Kedar,P.S., Kim,S.J., Robertson,A., Hou,E., Prasad,R., Horton,J.K. and Wilson,S.H. (2015) Structural and functional insights. *Science*, 349, 1754–1758.

49. Kedar,P.S., Kim,S.J., Robertson,A., Hou,E., Prasad,R., Horton,J.K. and Wilson,S.H. (2015) The assembly of the closed DNA polymerase β–DNA ligase I complex. *EMBO J.*, 34, 1731–1742.

50. Rasmussen,L.J. (2009) Nuclear translocation contributes to early onset cataract in mice. *IUBMB Life*, 61, 697–706.

51. Cooper,P., VandeWoude,F. and Bunn,H.F. (2000) The nuclear localization of the DNA repair scaffold XRCC1: uncovering the functional role of a bipartite NLS. *Nucleic Acids Res.*, 28, 229–2303.

52. Marintchev,A., Gryk,M.R. and Mullen,G.P. (2003) Site-directed mutagenesis analysis of the structural interaction of the single-strand-break repair protein, X-ray cross-complementing group 1, with DNA polymerase β. *Nucleic Acids Res.*, 31, 580–588.

53. Tomkinson,A.E. and Wilson,S.H. (1995) Oxidative stress response and steroidogenesis. *Annu. Rev. Biochem.*, 64, 31–58.
